BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Research’s IPO Report
Tatva Chintan Pharma Chem Ltd. is a specialty chemicals manufacturer, with a diverse portfolio of structure directing agents (40% of revenues), phase transfer catalysts (27%), electrolyte salts (1%) for super capacitor batteries and pharmaceutical, agrochemical intermediates and other specialty chemicals (30%).
Indian specialty chemical market is expected to grow at 11.3% compound annual growth rate over CY19-24E (F&S report) versus 5.3% globally.
Further India’s chemical export is expected to grow at 13% CAGR (CY19-24E) versus China’s 7% due to China plus one strategy being adopted by majority of the global firms.
Tatva Chintan Pharma Chem is well placed to capture this opportunity with niche and diversified product portfolio across various industries.
Click on the attachment to read the full IPO report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.